Evidence map›Paper›PMID 29146657›Full record

Trial reportBMJ open2017

A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus.

Michael Alan Glaysher, Aruchuna Mohanaruban, Christina Gabriele Prechtl, Anthony P Goldstone, Alexander Dimitri Miras, Joanne Lord, Navpreet Chhina, Emanuela Falaschetti, Nicholas Andrew Johnson, Werd Al-Najim and 11 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02459561 (A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02459561 naunknown statusnot on this map

A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes

TypeinterventionalSponsorImperial College LondonRan2015 to 2019Enrolled170ConditionsOverweight and Obesity, DiabetesArmsEndoBarrier TM Gastrointestinal Liner, Best Medical Care
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 2 countries.

Michael Alan GlaysherSouthampton Biomedical Research Centre, University Hospital Southampton, Southampton, Hampshire, UK.
Aruchuna MohanarubanImperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Christina Gabriele PrechtlDepartment of Public Health, Imperial College London, Imperial Clinical Trials Unit, London, UK.
Anthony P GoldstonePsychoNeuroEndocrinology Research Group, Neuropsychopharmacology Unit, Centre for Psychiatry and Computational, Cognitive and Clinical Neuroimaging Laboratory, Division of Brain Sciences, Imperial College London, London, UK.
Alexander Dimitri MirasDivision of Diabetes, Endocrinology and Metabolic Medicine, Hammersmith Hospital, London, UK.
Joanne LordSouthampton HTA Centre, University of Southampton, University of Southampton Science Park, Southampton, UK.
Navpreet ChhinaComputational Cognitive and Clinical Neuroimaging Group, Hammersmith Hospital, Imperial College London, London, UK.
Emanuela FalaschettiImperial Clinical Trials Unit, Imperial College London, London, UK.
Nicholas Andrew JohnsonSchool of Public Health, Imperial College London, London, UK.
Werd Al-NajimDepartment of Investigative Medicine, Imperial College London, London, UK.
Claire SmithImperial Clinical Trials Unit, Imperial College London, London, UK.
Jia V LiDivision of Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Mayank PatelDepartment of Diabetes and Endocrinology, Southampton General Hospital, Southampton, UK.
Ahmed R AhmedImperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Michael MoorePrimary Care Medical Group, University of Southampton Medical School, Southampton, UK.
Neil PoulterImperial Clinical Trials Unit, Imperial College London, London, UK.
Stephen BloomNorth West London Pathology, Head of Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Hospital, London, UK.
Ara DarziDivision of Surgery, Imperial College London, London, UK.
Carel Le RouxHead of Pathology, University College Dublin, Dublin, Ireland.
James P ByrneDivision of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Julian P TeareDepartment of Gastroenterology, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
Imperial College London · GBHammersmith Hospital · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Southampton · GBImperial College Healthcare NHS Trust · GBSouthampton General Hospital · GBSt Mary's Hospital · GBSt. Mary's Hospital · GBUniversity College Dublin · IE

Funding

Medical Research Council G0902002Medical Research Council MC_PC_14139Wellcome Trust
6 · The paper itself

Abstract

introductionThe prevalence of obesity and obesity-related diseases, including type 2 diabetes mellitus (T2DM), is increasing. Exclusion of the foregut, as occurs in Roux-en-Y gastric bypass, has a key role in the metabolic improvements that occur following bariatric surgery, which are independent of weight loss. Endoscopically placed duodenal-jejunal bypass sleeve devices, such as the EndoBarrier (GI Dynamics, Lexington, Massachusetts, USA), have been designed to create an impermeable barrier between chyme exiting the stomach and the mucosa of the duodenum and proximal jejunum. The non-surgical and reversible nature of these devices represents an attractive therapeutic option for patients with obesity and T2DM by potentially improving glycaemic control and reducing their weight. METHODS AND ANALYSIS: In this multicentre, randomised, controlled, non-blinded trial, male and female patients aged 18-65 years with a body mass index 30-50 kg/m TRIAL REGISTRATION NUMBER: ISRCTN30845205, ClinicalTrials.gov Identifier NCT02459561.

Indexed as

AdolescentAdultAgedBody Mass IndexDiabetes Mellitus, Type 2DuodenumEndoscopyEquipment DesignFemaleGastric BypassGlycated HemoglobinHumansJejunumLogistic ModelsMaleMiddle AgedGlycated Hemoglobinduodenal-jejunal bypass linerduodenal-jejunal bypass sleeveendobarrierobesitytype 2 diabetes mellitus

Identifiers

PMID29146657
PMCPMC5695522
OpenAlexW2769411730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.